The promise of selective MET inhibitors in non-small cell lung cancer with MET exon 14 skipping - Cancer Treatment Reviews
Early Alectinib Resistance From MET Amplification in ALK Rearranged NSCLC: Response to Crizotinib with Re-response to Alectinib and Crizotinib - Clinical Lung Cancer
MET/HGF pathway activation as a paradigm of resistance to targeted therapies - Ko - Annals of Translational Medicine
MET Signaling: Novel Targeted Inhibition and Its Clinical Development in Lung Cancer - Journal of Thoracic Oncology
MET inhibitors for targeted therapy of EGFR TKI-resistant lung cancer | Journal of Hematology & Oncology | Full Text
BRAF V600E mutation and MET amplification as resistance pathways of the second-generation anaplastic lymphoma kinase (ALK) inhibitor alectinib in lung cancer - Lung Cancer
MET/HGF pathway activation as a paradigm of resistance to targeted therapies - Ko - Annals of Translational Medicine
Non-small cell lung cancer-small cell lung cancer transformation as mechanism of resistance to tyrosine kinase inhibitors in lung cancer
MET Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling | Science
Targeting the MET Pathway for Lung Cancer Treatments, Biomarkers
MET Oncogene in Non-Small Cell Lung Cancer: Mechanism of MET Dysregulation and Agents Targeting the HGF/c-Met Axis. - Abstract - Europe PMC
Targeting MET in Lung Cancer: Will Expectations Finally Be MET? - ScienceDirect
Introduction - Targeting METex14 NSCLC - Text Module - MET Inhibition in NSCLC - Oncology - Clinical Care Options
Targeting MET in Lung Cancer: Will Expectations Finally Be MET? - Journal of Thoracic Oncology
MET increased gene copy number and primary resistance to gefitinib therapy in non-small-cell lung cancer patients - Annals of Oncology
DISSECT platform with multi-omics data and various analytic tools - CNGBdb
Novel Therapies for Metastatic Non-Small Cell Lung Cancer with MET Exo | LCTT
Chidamide increases the sensitivity of non-small cell lung cancer to crizotinib by decreasing c-MET mRNA methylation | bioRxiv
new-molecular-drivers-in-nsclc-the-role-of-met
Reciprocal and Complementary Role of MET Amplification and EGFR T790M Mutation in Acquired Resistance to Kinase Inhibitors in Lung Cancer | Clinical Cancer Research
Treatment of Non–Small-Cell Lung Cancer with Erlotinib or Gefitinib
Targeting MET in Cancer: Obstacles and Potentials | Insight Medical Publishing
MET amplification and epithelial-to-mesenchymal transition exist as parallel resistance mechanisms in erlotinib-resistant, EGFR -mutated, NSCLC HCC827 cells | Oncogenesis
MET inhibitors for targeted therapy of EGFR TKI-resistant lung cancer | Journal of Hematology & Oncology | Full Text
MET amplification increases the metastatic spread of EGFR-mutated NSCLC - Lung Cancer
